|Day Low/High||40.06 / 40.59|
|52 Wk Low/High||35.30 / 43.30|
Stocks declined on Tuesday as wild weather stifled activity and led to low volume.
Why the name is sagging, and what it will take to spur the sector higher.
U.S. stock futures and shares in Europe and Asia trade mixed Tuesday ahead of Donald Trump's first speech to a joint session of Congress.
Markets in Asia attempted to bridge the gap between U.S. and European markets overnight before paring gains as the session wound to a close
There are nearly too many surging sectors to count.
Jim Cramer compares Allergan's growth to other pharma stocks.
AstraZeneca posted stronger-than-expected earnings in the fourth quarter but was hesitant about 2017.
Here is a round-up of the headlines from Europe.
Alexion Pharmaceuticals has fired its CEO and CFO as an ongoing investigation into sales practices continues.
AstraZeneca reported optimistic results for its lung cancer drug Tagrisso in a trial, saying it improved progression-free survival by nearly six months.
For the week of November 7, all eyes will be on Tuesday's presidential election.
Stocks in the health care sector seem to have no underpinnings whatsoever.
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
Given predictable upcoming catalysts and a large addressable market, this small-cap biotech is a buy.
Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
Pfizer's second acquisition this week could add risk. Some retailers attract portfolio managers.
Pfizer is making another acquisition.
Another busy day on the earnings calendar kept trading erratic again on Thursday, though the S&P 500 and Nasdaq managed to clinch slight gains by the end of the session.
Barring a strong rally over $31 that has follow-through, we look for AZN to slowly erode.
Good morning! Bret Jensen here! It's good to be standing in for Doug Kass on Doug's Daily Dairy this Friday, especially on a day when my "Best Idea" Relypsa (RLYP) is likely to soar. After the bell Thursday, the U.S. Food and Drug Administration ess...
Inovio Pharmaceuticals and Eagle Pharmaceuticals both boast solid pipelines and sound balance sheets.